Pharma Pulse 10/1/24: Lessons Learned from Risk Mitigation, HCPs Preferred Source of Contraceptive Info Among AYAs & more

LogiPharma USA 2024: Lessons Learned from Risk Mitigation

Brendan Ryan, counterintelligence risk chief, supply chain and cyber directorate (SCD) at the Office of the Director of National Intelligence (ODNI) moderated a panel on “The Evolving Threat Landscape—The US Government’s Lessons Learned for Mitigating Risk Across the Pharma Supply Chain.” He was joined by Peter Battaglia, deputy director, mission assurance division, Department of Defense (DoD) Logistics Agency; Jeanette McMillian, assistant director, National Counterintelligence and Security Center’s SCD, ODNI; and Leigh Verbois, PhD, director at the Office of Drug Security, Integrity and Response at the FDA.

Survey Shows HCPs Are Preferred Source For Contraceptive Information Among AYAs

Access to contraceptive information is significant for the sexual and reproductive well-being of adolescents and young adults (AYA). Such information can encourage AYAs to practice informed decision-making and bodily autonomy, whereas inaccurate information can be harmful. Authors of a study published in JAMA Network Open examined AYA patients’ preferred and actual sources of contraceptive information. Additionally, they assessed associations present with the reporting of sufficient information.

Venture Mega-Rounds Return to Biotech

The number of deals for $100 million or more have put biotech on pace to come close to full-year 2021’s record total, industry data show.

ImmunoTek Celebrates International Plasma Awareness Week

ImmunoTek Bio Centers is excited to announce their participation in International Plasma Awareness Week (IPAW) from October 7-11, 2024. The community is invited to experience Plasma Mania happening during this special week in both divisions of ImmunoTek Bio Centers – ImmunoTek Plasma and Freedom Plasma. The week-long celebration is dedicated to raising awareness about the vital role plasma donations play in saving lives and improving patient outcomes worldwide.

Fleming CFO, Inc. on LinkedIn

Macroeconomic pressures, the need for agility, and the rising complexity of clinical studies are driving the adoption of the Functional Service Provider (FSP) model in pharma. FSPs offer the flexibility and scalability needed to accelerate drug development and adapt to an evolving landscape.

Parexel's EVP, Jenny Denney, discusses the benefits and considerations of using FSPs in life sciences in an interview with Pharmaceutical Executive.

#pharma| #pharmaceuticalindustry| #lifesciences

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs